The miR‐3127‐5p/p‐<scp>STAT</scp>3 axis up‐regulates <scp>PD</scp>‐L1 inducing chemoresistance in non‐small‐cell lung cancerDongfang Tang, Yifeng Sun|Journal of Cellular and Molecular Medicine|2018Cited by 76
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Gening Jiang, Zheng Ruan et al.|Signal Transduction and Targeted Therapy|2024Cited by 30